Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants
Veerachai Watanaveeradej, Sriluck Simasathien, Ananda Nisalak, Timothy P Endy, Richard G Jarman, Bruce L Innis, Stephen J Thomas, Robert V Gibbons, Sumetha Hengprasert, Rudiwilai Samakoses, Angkool Kerdpanich, David W Vaughn, J Robert Putnak, Kenneth H Eckels, Rafael De La Barrera, Mammen P Mammen Jr, Veerachai Watanaveeradej, Sriluck Simasathien, Ananda Nisalak, Timothy P Endy, Richard G Jarman, Bruce L Innis, Stephen J Thomas, Robert V Gibbons, Sumetha Hengprasert, Rudiwilai Samakoses, Angkool Kerdpanich, David W Vaughn, J Robert Putnak, Kenneth H Eckels, Rafael De La Barrera, Mammen P Mammen Jr
Abstract
A Phase I/II observer-blind, randomized, controlled trial evaluated the safety and immunogenicity of a dengue virus (DENV) vaccine candidate in healthy Thai infants (aged 12-15 months) without measurable pre-vaccination neutralizing antibodies to DENV and Japanese encephalitis virus. Fifty-one subjects received two doses of either DENV (N = 34; four received 1/10th dose) or control vaccine (N = 17; dose 1, live varicella; dose 2, Haemophilus influenzae type b). After each vaccine dose, adverse events (AEs) were solicited for 21 days, and non-serious AEs were solicited for 30 days; serious AEs (SAEs) were recorded throughout the study. Laboratory safety assessments were performed at 10 and 30 days; neutralizing antibodies were measured at 30 days. The DENV vaccine was well-tolerated without any related SAEs. After the second dose, 85.7% of full-dose DENV vaccinees developed at least trivalent and 53.6% developed tetravalent neutralizing antibodies ≥ 1:10 to DENV (control group = 0%). This vaccine candidate, therefore, warrants continued development in this age group (NCT00322049; clinicaltrials.gov).
Figures
Source: PubMed